| abstract |
The invention relates to recombinant MVA, which is able to express HCV structural antigens, functional parts of these structural antigens or epitopes of these structural antigens. The invention further describes a pharmaceutical preparation which is in particular in the form of a vaccine and contains a recombinant MVA according to the invention, eukaryotic cells which contain the recombinant MVA according to the invention and various uses of the recombinant MVA, for example for the production of recombinant structural proteins, for the production of a pharmaceutical preparation , which is particularly suitable for the therapy and prophylaxis of HCV infections and diseases caused thereby, processes for the production of recombinant MVA and of recombinant HCV structural polypeptides which are encoded by this recombinant MVA, and DNA or RNA of this recombinant MVA. |